TG Therapeutics (TGTX) and Neuraxpharm Announce Ex-US Commercialization Agreement for BRIUMVI
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall St tumbles on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil drops $1 as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
TG Therapeutics and Neuraxpharm Announce Ex-US Commercialization Agreement for BRIUMVI® (ublituximab-xiiy)
August 1, 2023 7:00 AM EDTTotal deal size of approximately ~$650M, including over $150M in upfront and near-term milestones
Neuraxpharms dedicated neurology focus and established European presence makes them an attractive partner for BRIUMVIs European launch, targeted within the next six months
TG retains strategic flexibility with an option to buy back all rights under this agreement if TG is acquired
Conference call to be held today, August 1, 2023 at 8:30 AM ETNEW YORK and DÃœSSELDORF, Germany, Aug. 01, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) (TG) and Neuraxpharm Group (Neuraxpharm), a... More
